Completion lymphadenectomy may not increase in-transit disease in malignant melanoma.
Russell-Jones
Robin
R
Healy
Ciaran
C
Powell
Ann-Marie
AM
Acland
Katharine
K
O'Doherty
Michael
M
Calonje
Eduardo
E
D000970:Antineoplastic Agents / Q000627:therapeutic use; D015331:Cohort Studies; D000075202:Contraindications; D018572:Disease-Free Survival; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008197:Lymph Node Excision / Q000379:methods; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000556:secondary* / Q000601:surgery*; D009364:Neoplasm Recurrence, Local; D021701:Sentinel Lymph Node Biopsy / Q000379:methods
D000970:Antineoplastic Agents; D007372:Interferons